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IschemiaStem cell (SC) therapy represents a big hope for treating unmet clinical needs, including in the context of
cardiovascular disease. The abilities of embryonic SC (ESCs) to self-renew indeﬁnitely and to differentiate in all the
three germ layersmake these SCs very attractive for both basic science investigations and clinical therapies. ESCs can
generate vascular endothelial and mural cells to be used for transplantation and to create engineered organs.
Moreover ESC can be used to mimic developmental vasculogenesis and angiogenesis in vitro. However, additional
studies are needed to improve vascular differentiation protocols of ESCs. This review focuses on ESCs and the
technologies allowing for their differentiation into mesoderm and vascular lineage. Moreover, the potential of ESC-
derived vascular cells for clinical cardiovascular therapies and strategies to improve ESC engraftment efﬁciency are
discussed.
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Cardiovascular disease (CVD) is the principal cause of death and
disability in the world. Among CVD, ischemic diseases are the most
frequent. The occlusion of larger arteries can be often treated by surgical
revascularization or angioplasty. However, these interventions are notRegeneration, University of
lin Street, BS2 8HW Bristol,
3904.
li).
NC-ND license.always possible and in addition they are frequently complicated by vein
graft or restenosis. Moreover, impaired microcirculation signiﬁcantly
contributes to tissue ischemia and this cannot be treated by vascular
surgery or interventional cardiology. As a consequence, the long-term
clinical complications of ischemia, including heart failure and critical
limb ischemia, continue to rise. Therapeutic approaches able to induce
neovessel growth and consequently improve blood perfusion in
ischemic tissue are considered promising. In particular, stem cell (SC)
therapy pre-clinical and clinical trials have opened new therapeutic
perspectives and big expectations (Cheung and Sinha, 2011; Li et al.,
2009a; Sieveking and Ng, 2009). Recent research point to the vascular
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therapeutic beneﬁt potentially resulting from transplanting SC derived
from a number of sources in ischemic tissues (Lasala and Minguell,
2011; Leeper et al., 2010). The focus of this review is on pluripotent
embryonic SCs (ESCs) and their capacity to differentiate into vascular
cells.
2. Embryonic stem cells
ESCs are derived from the inner cell mass (ICM) of blastocyst stage
embryos. They have generated much interest because of their unique
ability to self renew indeﬁnitely while maintaining the potential to give
rise to all cell types in the human body (Kiskinis and Eggan, 2010;
Reubinoff et al., 2000; Thomson et al., 1998). The ﬁrst murine ESC
(mESC) lines were successfully derived directly from blastocyst in 1981
(Evans and Kaufman, 1981; Martin, 1981). The initiative to derive
pluripotent cell lines from early embryos was inspired by studies of
teratocarcinoma cells, which propagate from explanted tumors and can
contribute to multiple tissues when injected into host blastocysts to
form chimeras (Brinster, 1974). The culture regime for retaining pluri-
potency includes a feeder layer of mitotically inactivated mouse ﬁbro-
blasts and the presence of leukemia inhibitory factor (LIF); the removal
of LIF from culture induced mESCs to spontaneously differentiate into
all 3 primitive germ layers (Doetschman et al., 1985). The ﬁrst human
ESC (hESC) line was established by Thomson and colleagues in 1998
(Thomson et al., 1998) and since then intense research to direct and
elucidate differentiation pathways of hESC has been ongoing and
growing. The requirement for MEF feeder cells to support undiffer-
entiated hESCs can be overcome by the addition of FGF-2 and other
factors, but not LIF, to the culture medium (Ludwig et al., 2006). There
are similarities between human and mouse ESCs in the expression of
key transcription factors, including Oct3/4, Nanog and Sox2, which
maintain pluripotency and self-renewal. However, fundamental
species-speciﬁc differences are demonstrated, such as: 1) The average
population-doubling time of hESCs (36 h) is longer than that of mESCs
(12 h), making hESCs difﬁcult to culture; 2)Morphogically, hESCs grow
in ﬂat colonies with distinct cell borders in monolayer culture whereasEmbryonic Stem 
Cells (ESC) 
Mesode
Smooth Muscle 
Cells (SMC) 
AP; Oct3/4; Sox2; Nanog; Flk1 
(h); Rex1; SSEA-1 (m); SSEA-3/4 
(h); Tra-1-60 (h); Tra-1-81 (h);  
T;  BMP2/4; Nodal;
CD34; Sca1; N-Ca
MIXL1; PDGFR-α; V
Cryptic  
αSMA; SMMHC; Smoothelin; 
Calponin; SM22α; Calmodulin; 
Caldesmon; Desmin; Vimentin 
AP, Alkaline Phosphatase ; 
(m), murin  ESC expression only; 
(h), human ESC expression only  
Fig. 1. Schematic overview of cell surface marker expression during mesoderm speciﬁcation
are modulated: from the pluripotency of ESC, through their mesodermal commitment an
selective markers utilized to deﬁne and track the different steps of vascular differentiationmESCs grow in more rounded clumps with indistinct cell borders; 3)
Differences in surface antigens amongpluripotent hESCs, which express
stage-speciﬁc embryonic antigen SSEA-3 and SSEA-4 and lack SSEA-1,
andmESCs, expressing SSEA-1, but lacking SSEA-3 and SSEA-4 (Ginis et
al., 2004; Pera et al., 2000; Thomson et al., 1998) (Fig. 1). Moreover,
hESCs have unclear individual epigenetic proﬁles which can affect their
differentiation properties (Lagarkova et al., 2006) and their differenti-
ation response to stimuli is limited. These differences between murine
and human cultured ESCs have delayed hESC differentiation advances,
and many cell-type derivation studies are still conducted using mESCs.
ESCs are an attractive source for the derivation of large numbers of
cells to be used in various tissue repair and cell replacement therapies.
However upon transplantation into living organisms, undifferentiated
ESCs can spontaneously differentiate into proliferating teratomas,
which are a disordered amalgam of cells belonging to all three germs
layers. Therefore, there have been signiﬁcant efforts to stimulate ESC
differentiation and proliferation in a controlled manner. Indeed, in the
last decade, cardiovascular researchers have shown increased interest
in characterizing ESCs and controlling their differentiation towards
speciﬁc vascular lineages and to use this renewable pool of cells to
regenerate the diseased adult cardiovascular system.
3. Vascular system
3.1. Mesoderm differentiation during embryogenesis and mesoderm
markers
During early vertebrate embryogenesis, the ICM, which is the
internal cell component of the blastocyst, gives rise to the primitive
endoderm and epiblast, which consists of three primary germ layers:
ectoderm (outer), mesoderm (middle), and endoderm (inner), from
which all organ tissues are developed (Fig. 2). Vascular cells including
endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) are
predominantly descendants of mesodermal cells, although a diversity
in the smooth muscle lineage has been demonstrated in the chick
embryo showing an ectoderm origin for VSMCs (Topouzis andMajesky,
1996). To understand the differentiation of ESCs into mesodermalrm 
Vascular 
Progenitor Cells 
(VPC) 
Endothelial Cells 
(EC) 
 CD31; 
dherin; 
EGFR-2; 
CD34; PDGFR-β; 
VEGFR-2; CD31; c-kit  
CD31; CD34; Flt1; Flk1; 
VE-Cadherin; CD106; 
eNOS; Tie1; tie2; vWF 
Pericytes 
αSMA; Desmin; NG-2, 
PDGFR-β; CD146; RGS5;  
Aminopeptidase A/N;  
and vascular cell derivation from ESCs.During vascular speciﬁcation, speciﬁc markers
d VPC lineage, into their derivation into endothelial and mural lineage. A map of the
can be made.
Inner Cell Mass 
(ICM)
Ectoderm
Endoderm
Mesoderm
Axial 
mesoderm
Paraxial 
mesoderm
Intermediate
mesoderm
Lateral 
mesoderm
- Prechordal plate
- Notochord
Somites
- Muscles
- Bones
- Cartilage
- Gonads
- Kidney
- Adrenal cortex
Somatic Splanchnic
- Ventral dermis
- Parietal serosa
- Limb buds Mesenchymal 
cells
Connective 
tissue
Cardiovascular 
organs
Heart
Blood 
cells
Blood 
vessels
Blastocyst
Fig. 2. Schematic overview of the development of different organs from the mesoderm.During early vertebrate embryogenesis, the ICM gives rise to the three primary germ layers:
ectoderm, mesoderm and endoderm, from which all organ tissues are developed. Mesoderm layer forms distinct developmental fates: axial, paraxial, intermediate, and lateral
mesoderm, in order of their proximity to the primitive streak. The lateral mesoderm gives rise to the somatic and splanchnic mesoderm. Somatic mesoderm forms ventral dermis,
parietal serosa and limb buds. Splanchnic mesoderm forms mesenchymal cells and connective tissue, and cardiovascular organs and blood cells.
269B. Descamps, C. Emanueli / Vascular Pharmacology 56 (2012) 267–279
C
u
rr
e
n
t
P
ro
s
p
e
c
ts
in
V
a
s
c
u
la
r
B
io
lo
g
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process of mesodermal tissue development and the different markers
characterizing mesoderm tissue (Kitagawa and Era, 2010; Tam and
Beddington, 1987).
Much of our understanding of germ layer formation comes from
studies in the amphibian embryo, particularly those of the frog Xenopus
laevis. The mesoderm is formed at the onset of gastrulation, around day
6.5 of gestation. Cells migrate from the epiblast through the primitive
streak and organize into the mesodermal germ layer (Lawson et al.,
1991). The mesodermal germ layer plays a fundamental role in or-
ganizing the vertebrate body axes, and the primitive streak is a key
structural marker to discriminate mesodermal precursor cells. Then, at
themid- to late-streak stage, themesoderm starts tomigrate away from
the primitive streak, and enters between the endoderm and ectoderm
layers to form distinct developmental fates: axial, paraxial, intermedi-
ate, and lateral mesoderm, in order of their proximity to the primitive
streak (Burdsal et al., 1993; Parameswaran and Tam, 1995; Poelmann,
1981) (Fig. 2). Precursors of the lateral mesoderm give rise to the
cardiovascular organs (heart, blood vessels) and other structures
such as kidney, gonads, dermis, cartilage, muscles, and blood cells.
Selective markers are utilized to deﬁne and track the differentia-
tion of mesodermal cells in culture as the induction, patterning,
and speciﬁcation of mesoderm represent a complex sequence of
events that are thought to be regulated through the interplay of
molecules (Doss et al., 2012; Kitagawa and Era, 2010) (Fig. 1).
Brachyury (also known as “T”) is required in the early determina-
tion and differentiation of mesoderm (Beddington et al., 1992), but
is then downregulated when cells undergo speciﬁc development
into mesoderm-derived tissues, including cardiac muscle, endo-
thelium and blood cells (Kispert and Herrmann, 1994). Brachyury
is thus considered to be one of the best markers of early mesoderm
differentiation, and is used widely in the ﬁeld of developmental
biology to track the development of this germ layer (Fehling et al.,
2003). Additional mesoderm markers have been identiﬁed. Bone
morphogenetic protein (BMP)2, the member of the Transforming
Growth Factor (TGF)-β superfamily, is a late mesodermal markerexpressed during vertebrate development. BMP2 plays crucial role
in early embryonic patterning (Zhang and Bradley, 1996) and its
expression immediately follows the transient expression of Brachyury
in the nascent mesoderm. MIXL1, a homeobox gene involved in the
early hemangioblastic and hematopoietic speciﬁcation, is another
marker of the primitive streak and is suitable for the isolation of primi-
tive hematopoietic precursors, including hemangioblasts (Davis et al.,
2008). Other markers such as Nodal, CD31, CD34, Sca-1 or N-Cadherin
are also expressed during mesoderm commitment. Two cell surface
markers, Platelet-derived Growth Factor Receptor (PDGFR)-α and Vas-
cular Endothelial Growth Factor Receptor (VEGFR)-2, are also indicators
of mesoderm development and can be utilized to isolate mesodermal
cells (Sakurai et al., 2006) (Fig. 1).
3.2. Vascular morphogenesis
The development of a mature vascular system is a complex process,
which requires ﬁne regulation and the use of different kinds of cells:
SCs, progenitor cells, vascular ECs and mural cells. Mural cells are
composed by VSMCs and pericytes and interact with ECs to form the
complex network of capillaries, arterioles, arteries, and veins.
In the embryo, blood vessels arise from endothelial precursors,
which assemble into a primitive vascular network of small capillaries;
this process is known as developmental vasculogenesis (Fig. 2). In
mammals, extra-embryonic vasculogenesis precedes intra-embryonic
vascular development and is initiated shortly after gastrulation. En-
dothelial precursor cells emerged mainly from mesodermal precursors
(Jin and Patterson, 2009; Pardanaud et al., 1996), and at this stage, they
already express markers such as CD31, CD34 and VEGFR-2 (Fig. 1)
(Cleaver and Melton, 2003; Ema et al., 2006). It's interesting to notice
that the development of the hematopoietic and endothelial lineages
occurs in very close association. This may explain why some markers
such as CD34, CD31 and VE-Cadherin are common for the 2 cell
lineages. At themoment, the origin of hematopoietic stem cells (HSC) is
still controversial and a common origin from a bipotential precursor,
the hemangioblast, has been proposed for the hematopoietic and
Table 1
Different methods to derive in vitro vascular cells from embryonic stem cells.
Cell lines Derived cells Models of differentiation In vitro characterization In vivo application References
Embryoid
body formation
hESC H9 EC EB, then CD31+
cell sorting on gelatin
Ac-LDL uptake, tube formation in
Matrigel and express CD31, CD34,
Flk1, N/VE-Cadherin, vWF
Microvessel formation
(with blood cells) after
transplantation into SCID mice
(Levenberg et al.
(2002, 2010)
hESC H9 and H1 EC EB cultured with
hematopoietic cytokines
during 15 days, then
CD45neg cell sorting
cultured on ﬁbronectin
with VEGF-A
Ac-LDL uptake and express CD31,
CD144, CD34, vWF, eNOS, endothelin,
Tie2, neuropilin
Chadwick et al. (2003);
Wang et al. (2004)
mESC 129 SvJ and
R1
EC/SMC/
Pericytes
EB plated on gelatin or
in 3D collagen gel
with VEGF-A165 treatment
Form vascular network (lumenized
in large vessels) and express CD31,
Flk1, αSMA, NG2
Jakobsson et al.
(2006, 2007)
hESC CHA3 EC EB and attachment in EC
medium; then
mechanical isolation and
vWF+ cell sorting
Cobblestone morphology, Ac-LDL uptake,
vascular network formation in Matrigel
with lumen structures and express
CD31, CD144, Tie2, Flk1, vWF
Blood perfusion and limb
salvage improvement
with neovascularization
in HLI model
Cho et al. (2007)
hESC H1 and H9 SMC EB plated on gelatin and
cultures in smooth
muscle growth medium
(Cambrex), then
re-plated in normal medium
Spindle shape morphology, contract to
Carbachol and express αSMA, SMMHC,
calponin, caldesmon, SM22α,
smoothelin and myocardin
Xie et al. (2007)
hESC H9 EC EB cultivated with BMP4; then
CD133+Flk1+
cell sorting cultured on
ﬁbronectin
Activated to TNFα, form tubes in Matrigel,
Ac-LDL uptake, migrate in wound-healing
assay and express CD31, CD34, CD144
Goldman et al. (2009)
Rosa 26 and T GFP
mESC/hESC H9
CD31+
/CD34+
endothelial
precursors
EB plated on Gelatin;
then VEGF+/VEGF
coreceptor neuropilin-1+
cell sorting
Form endothelial-like colonies in Matrigel Cimato et al. (2009)
hESC H9 EC EB suspended in collagen-I
gel, cultured in
EGM2 with KO serum
replacement+VEGF+
bFGF; then CD31+/CD144+
cell sorting
cultured on ﬁbronectin
Cobblestone morphology, Ac-LDL uptake,
form tubes in Matrigel and express CD31,
CD144 and vWF
Form functional vessels
in vivo in mice, and
improve cardiac function
in MI model
Li et al. (2009b)
mESC EC EB plated in methylcellulose
with FGF-2
and VEGF, under hypoxia
Form sprouts and express CD31 Han et al. (2010a)
mESC D3 EC EB plated on gelatin; after 3
weeks: CD144+
cell sorting and VEGF treatment
Tube formation in Matrigel, Ac-LDL uptake
and express CD144, vWF, eNOS
Revascularization and functional
improvement in HLI model
N.F. Huang et al. (2010)
hESC H9 and H13 EC and SMC EB, then CD34+ cell sorting for
VPC isolation
(10 days) cultured with EC:
VEGF-A165 or
with SMC: PDGF-BB
EC: cobblestone morphology, Ac-LDL uptake
and express CD31, CD34, Flk1, CD144 and vWF
SMC: spindle shape morphology, contract/relax
to Carbachol/atropine and express αSMA,
SMMHC, calponin, caldesmon and SM22α
Microvessel formation (some
with blood cells) after transplantation
into SCID mice
Levenberg et al. (2010)
hESC H7 and H1 EC EB treated with VEGF-A165; then CD31+ cell
sorting
Response to TNFα and express CD31, CD144, vWF Lumenized vessel formation
after implantation
in rat onto scaffold or
embedded in collagen gel
Nourse et al. (2010)
hESC RUES1 EC EB on Matrigel with cytokines
(BMP4, Activin
A, FGF-2, VEGF-A) and
inhibition of TGF-β
CD144 promoter screen: hVPr-GFP+ cells James et al. (2010)
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mESC R1 SMC EB plated on gelatin or in 3D
Matrigel under
inhibition by TGF-β siRNA transfection
αSMA, myocardin expression Han et al. (2010b)
Serial
differentiation
Monkey ESC lines EC and SMC Cocultured on OP9 feeder layer; then
Flk1+/CD144− cell sorting cultured
EC: on OP9 or SMC: on collagen IV
EC: express CD144, eNOS, CD31
SMC: express αSMA, calponin
Flk1+ cells can form vascular structures
in collagen gel
Sone et al. (2003)
mESC E14.1 strain VSMC
and pericyte
5-day cocultured on OP9 feeder layer Form vascular sprouts on collagen-I gel
and express acta2, cnn1, actg2
On collagen: express SMMHC, NG2
Lindskog et al. (2006)
hESC H1 and H9 EC Cocultured on MEF, then CD34+
cell sorting
cultured on gelatin with
VEGF-A and FGF-2
Ac-LDL uptake, tube formation in Matrigel
and express CD31, CD144, CD105, vWF,
VEGFR, Tie2, EphB4, EphrinB2
Arborization of blood vessels
integrated in host vascular
system after injection in SCID mice
Wang et al. (2007)
hESC H1 and H9 EC Cocultured on S17 and M210;
then CD34+
/CD31+/Flk1+ cell sorting cultured on
ﬁbronectin and EGM2
Ac-LDL uptake, tube formation in Matrigel
and express CD31, vWF
Woll et al. (2008)
hESC H9 EC and SMC Cocultured on S17 or M2
10B4 stromal cells;
then CD34+ cell sorting
cultured on ﬁbronectin
with cytokines (EGM2 for EC;
PDGF-BB and
TNFα for SMC)
EC: cobblestone morphology, Ac-LDL uptake,
presence of microparticules at membrane surface
and express CD31, Flk1, CD144, CD146, vWF, eNOS, Tie2
SMC: spindle shape morphology and express αSMA,
SMMHC, calponin, myocardin, SM22α, APEG-1 and CRP2
EC and SMC together form robust 3D vascular
network in Matrigel
Hill et al. (2010)
2D
monolayer culture
mESC CCE EC and SMC Monolayer on Coll-IV; Then
Flk1+ cell sorting
cultures on Coll-IV with EC:
VEGF-A; SMC: PDGF-BB
EC: Ac-LDL uptake and express CD31, CD144, CD34,
CD105 SMC: express αSMA, PDGFR-β, α-smTm, desmin
Flk1+ cells from tubes in 3D culture system
Flk1+ cells contribute to the
developing vasculature
of chick embryos
Yamashita et al. (2000)
mESC D3 EC Monolayer on Coll-IV
cultured in deﬁned
medium with VEGF-A, under
laminar shear stress
Form tubes in Matrigel and express Flk1,
eNOS, CD31, CD133, CD106
Incorporate neovessels in
HLI and have ability to
repair injured vessels
Zeng et al. (2006)
mESC D3 EC and SMC Monolayer on Coll-IV; then
Sca-1+ cell sorting
cultured on collagen IV with EC:
VEGF-A; SMC: PDGF-BB
EC: cobblestone morphology, Ac-LDL uptake
and express CD31, CD106, CD144, Flt1, Flk1
and vWF SMC: spindle shape morphology,
contract to Carbachol and express αSMA,
PDGFR-β, caldesmon, SM22α and NG2
EC: form vessels in Matrigel
xenograft and the
neo-endothelium covers
injured area in murin HLI
Xiao et al. (2006, 2007)
mESC and hESC
HUES3
SMC Monolayer plated on gelatin,
cultured with retinoid acid
Spindle shape morphology, contract to
Carbachol and express αSMA, SM22α,
calponin, desmin, SMMHC
(Huang et al.
(2006); H. Huang
et al. (2010))
mESC MGZ5 EC Monolayer on Coll-IV; then,
Flk1+ cell sorting
cultured on Coll-IV under
cyclic shear stress
Expression of αSMA, SM22α and SMMHC Shimizu et al. (2008)
mESC D3 and R1 EC Monolayer on Coll-IV; then
Flk1+ cell sorting
cultured on Coll-IV with VEGF
Cobblestone morphology and express CD31 Blancas et al. (2008)
mESC MGZ5 EC Monolayer on Coll-IV; then,
Flk1+ cell sorting
cultured on Coll-IV under
laminar shear stress
Expression of EphrinB2 Masumura et al. (2009)
mESC D3 SMC Monolayer on Coll-IV
cultured in deﬁned
differentiation medium for 12 days
Contract to Carbachol/KCl and express
αSMA, SM22α, SMMHC and calponin
Margariti et al. (2009);
Pepe et al.
(2010); Xiao et al. (2009)
hESC khES-1 and
khES-3
EC Generation of spheres by
ﬂoating culture, cultured
on gelatin with VEGF-A, BMP4,
SCF, FLT3L, IL3, IL6
Cobblestone morphology, Ac-LDL uptake,
form tubes in Matrigel and express CD31,
eNOS, CD144, VEGFR, Tie2 and vWF
Recruited into neovessels in
Matrigel plug assay in vivo
Nakahara et al. (2009)
(continued on next page)
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Table 1 (continued)
Cell lines Derived cells Models of differentiation In vitro characterization In vivo application References
Pluristem 129S6
mESC
EC Monolayer treated with DNA
methyltransferase
inhibitor (Aza-dC) during 15 days
Tube formation in Matrigel and express
CD144, vWF,Tie2
Banerjee and Bacanamwo
(2010)
hESC H9 SMC Monolayer on Coll-IV cultured
in differentiation
medium; then re-plated on
Coll-IV with PDGF-BB
and TGF-β1
Spindle shape morphology, contract to
Carbachol, produce ﬁbronectin/collagen,
and express αSMA, SM22α, calponin,
SMMHC; interact with EC to form longer
and thicker cord-like structures
Vo et al. (2010)
hESC H9 EC Monolayer on ECM from human
foreskin ﬁbroblasts
under hypoxic condition (5% O2)
Formation of vessel-like structure in 3D
Matrigel model and express VEGF-A/B,
Flk1, CD34, CD31 and vWF
Improvement of cardiac
function after MI in rat
Prado-Lopez et al. (2010)
hESC SA461 and
SA121
EC Monolayer on ﬁbronectin in
deﬁned differentiation
medium for 21 days
Cobblestone morphology, respond to
Carbachol and produce NO,
migrate in a scratch wound closing,
form tubes in Matrigel and express CD31,
CD144, Flk1and CD105
Injection of 10 day-progenitor
cells led to blood ﬂow
recovery and higher capillary
density in murin HLI
Kane et al. (2010)
hESC CHA4 EC and SMC Monolayer on Matrigel treated
with BMP4 and
inhibition of MEK/ERK,
then with VEGF-A and FGF-2;
then CD34+
cell sorting cultured in EC:
EGM2/VEGF-A/FGF-2; SMC:
EGM2/PDGF-BB/FGF-2
EC: cobblestone morphology, Ac-LDL
uptake, form tubes in Matrigel
and express CD31, CD34, CD144, Ang2
and vWF SMC: spindle shape morphology,
contract to Carbachol and express αSMA,
PDGFR-β, caldesmon, SM22α and NG2
hESC-EC form vessel-like structures
in Matrigel xenograft model
Transplantation of
hESC-derived CD34+ cells improve
perfusion and neovascularization
in murin HLI
Park et al. (2010)
mESC v26.2 B6
and v17.2
EC Monolayer with cytokines, especially BMP4 Ac-LDL uptake, form tubes in Matrigel and
express CD31 and CD144
Chiang and Wong (2011)
mESC R1, D3 and
E14
EC Monolayer cultured on ﬁbronectin with VEGF-A
and BMP4, then 2 puriﬁcations: Flk1+ cell
sorting cultured on ﬁbronectin with FGF-2 and
VEGF-A
Cobblestone morphology, Ac-LDL uptake, and express
Flk1, CD144, Flt1, Tie1, EphB4, EphrinB2
Blancas et al. (2011)
α-smTm: smooth muscle-speciﬁc alpha tropomyosin (a marker of fully differentiated smooth muscle); Ac-LDL: acetylated low-density lipoprotein; APEG-1/SPEG: aortic preferentially expressed protein 1 (marker for differentiated vascular
smooth muscle cells); CD105: endoglin (protein found in EC, but also in macrophages, ﬁbroblasts and SMCs); Coll-IV: collagen type-IV; CRP2/SLIM: cysteine-rich protein 2 (CRP2) (cofactor for SMC differentiation); Flt3-L: FMS-related
tyrosine kinase-3 ligand (hematopoietic cytokine); SCF: stem cell factor.
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yendothelial lineages (Cumano and Godin, 2007; Oberlin et al., 2010).
Indeed, VEGFR-2-positive cells in the primitive streak give rise to
hemangioblasts (both blood and endothelium), which migrate into the
extra-embryonic yolk sac to form structures known as blood islands.
The inner cells of the blood islands give rise to hematopoietic
progenitors whereas the outer cells are endothelial; they coalesce to
form a plexus of endothelial tubes that is then remodeled into a circu-
latory network (Coultas et al., 2005; Flamme et al., 1997). However,
recent studies have strongly supported the possibility that HSCs are
generated from hemogenic EC, revealing an endothelial origin of HSCs
(Cumano and Godin, 2007; Zovein et al., 2008).
Differentiation of ECs is governed by several factors, including the
immediate microenvironment, interactions with surrounding cells,
and the local release of cytokines and growth factors (GFs). Then,
angiogenesis phase occurs through the expansion of the vascular
plexus with vessels sprouting. Primitive vascular plexus remodels
into a highly organized vascular network; larger vessels ramify into
smaller ones and become surrounded by mural cells, which stabilize
the newly formed vessels and provide strength to control blood ﬂow
and blood pressure (Carmeliet, 2005; Risau, 1997).
Angiogenesis still occurs after birth, during the processes of organ
growth, repair and disease. In the adult organism, although most of
blood vessels remain quiescent, angiogenesis occurs physiologically in
the cycling ovary (Carmeliet, 2005). Moreover, in wound healing and
under pathological conditions such as ischemic diseases and cancer, ECs
can divide rapidly and reactivate angiogenesis.
3.3. Vascular cells
Blood vessels are thus composed of two interacting cell types: ECs
and perivascular cells referred to as VSMCs and pericytes, depending on
the type of vascular bed. ECs form a thinmonolayer called endothelium,
which line the interior surface of blood vessels and create an interface
between circulating blood in the lumen and the rest of the vessel wall.
The endothelium acts as a selective barrier to control the passage of
materials and gasses between the vessel lumen and surrounding tissue.
Proliferation, migration, invasion, cell networking and survival of ECs
ensure angiogenesis.
VSMCs are found within the blood vessel walls, in the tunica
media layer of large and small arteries and veins. VSMC function as
structurally supportive cells surrounding the endothelium of vessels
(Miano, 2010). VSMCs also control the caliber of blood vessels (es-
pecially resistance vessels) and the blood ﬂow through their intrinsic
contractile properties. Unlike skeletal and cardiac muscle, VSMCs are
not totally differentiated, and their mature phenotype can be in-
ﬂuenced by local environmental clues through several transcription
factors (Miano, 2010; Owens et al., 2004; Velican and Velican, 1980).
During vascular development, immature “synthetic” VSMCs play a
key role in blood vessel morphogenesis; they proliferate and migrate
and produce extracellular matrix (ECM) components of the blood
vessel wall such as collagen, elastin and proteoglycans. At the same
time, they also acquire their contractile properties (Owens et al.,
2004). VSMCs then differentiate into “contractile” VSMCs once the
vascular system is fully developed. During vascular injury, VSMCs de-
differentiate and plays a critical role in vascular repair by increasing
dramatically their proliferation and migration rates.
In contrast to larger vessels coated with multiple layers of VSMCs and
ECM, small blood vessels are composed of ECs surrounded by a basal
lamina and covered by pericytes (Cleaver and Melton, 2003). Pericytes
are solitary VSMC-like cells, and their density and morphology varies
between capillary networks in different tissues (Hellstrom et al., 1999).
Pericytes are morphologically, biochemically, and physiologically hetero-
geneous and play an essential role in angiogenesis (Bergers and Song,
2005). They are multipotent cells, retaining the capacity to differentiate
into VSMCs (Nehls and Drenckhahn, 1993) and a variety of other
mesenchymal cell types (Diaz-Flores et al., 1992; Sims, 2000). Pericytescommunicate directly with ECs, stabilize the newly formed endothelial
tubes, modulate blood ﬂow and vascular permeability, and regulate en-
dothelial proliferation, differentiation, migration and survival (Armulik et
al., 2005). At growing capillary tips, pericytes are attracted by PDGF-B
released by ECs in the vessel wall (Bergers and Song, 2005). They are
derived mainly by differentiation of local mesenchymal cells (Yamashita
et al., 2000) andmyoﬁbroblasts, and by proliferation of existing pericytes
(Hall, 2006). But a proportion of pericytes are also derived by migration
from the bone marrow (Song et al., 2005).
4. In vitro vascular differentiation models and markers
4.1. Variousmethods to differentiate embryonic stem cells into vascular cells
The potential use of ESCs in regenerative medicine may depend on
efﬁcient differentiation protocols to derive tissue-speciﬁc progenitor
cells. Different strategies have been used to induce in vitro differenti-
ation of ESCs. However, at present, no standardized protocol between
cell lines, differentiation models and culture manipulation exists for
generating vascular cells (Table 1). The different strategies could be
categorized into three culture methodologies: initiation of differentia-
tion through embryoid bodies (EBs) formation mimicking germ layer
formation, co-culture with ﬁbroblast feeder layers or mature target
cells, and monolayer culture of ESCs in deﬁned chemical conditions
followed by culture manipulations (Fig. 3).
In vitro derivation of vascular cells from pluripotent ESCs can be
achieved by differentiating spontaneously ESCs into multicellular EB
aggregates. EBs represent a physiological in vitro model for the early
stages of embryogenesis (including vascular development; see para-
graph on EB model). Supplementation of the EBs with cytokines
promotes their endothelial, smooth muscle cell and pericytes differ-
entiation (Han et al., 2010b; Jakobsson et al., 2007; Levenberg et al.,
2002; Wang et al., 2004). However, EB-based protocols have so far
proved inefﬁcient by giving a yield of 1–3% of ECs (Cho et al., 2007;
Levenberg et al., 2002; Li et al., 2008) and 10% of VSMCs (Xie et al.,
2007). Indeed, EBs formation permits not only the differentiation into
vascular cells (S.S. Chen et al., 2007; Lu et al., 2007;Wang et al., 2004),
but also into other various cells from all three germ layers. For
increasing efﬁciency, EB protocol requires EB dissociation and vascular
progenitor isolation using ﬂuorescence-activated cell sorting (FACS) or
magnetic-activated cell sorting (MACS) to obtain the desired cell type
and a homogenous cell population (Levenberg et al., 2002, 2010; Li et
al., 2008). Recently, improvements to EB-based protocols have been
reported, increasing the proportion of differentiated vascular cells.
These different methods employ addition of VEGF-A (Nourse et al.,
2010) or BMP4 (Goldman et al., 2009) to media components, a com-
bination of cell culture medium and extracellular matrix environment
(Xie et al., 2007) and inhibition of the TGF-β pathway (James et al.,
2010).
Modiﬁed approaches have been developed to avoid the use of EB
culture and to increase vascular cell differentiation efﬁciency. Serial
differentiation have been set up, notably by the co-culture method
allowing dissociated undifferentiated ESCs to be plated directly on
top of growth arrested mouse ﬁbroblast feeder layers such as mouse
embryonic ﬁbroblasts (MEF) (Wang et al., 2007), stromal cells (OP9,
S17, M210B4 and MS-5) (Hill et al., 2010; Lindskog et al., 2006; Sone
et al., 2003; Vodyanik et al., 2005), or mouse ECs (Kane et al., 2011;
Kaufman et al., 2001), which all promote vascular differentiation.
However, the co-culture method enables a production of not more
than 10% of CD34+ vascular progenitor cells (Wang et al., 2007),
which are then cultivated in deﬁned medium to enhance EC and SMC
yield (Table 1).
To date, the direct differentiation of ESCs towards a homogenous
vascular cell population and the isolation of derived vascular cells
without contamination of undifferentiated cells have been the critical
issues limiting human clinical trials. Plate coating with different
ESC ESC-derived 
vascular cells 
(SMC or EC)
EB 
formation
2D 
Monolayer
Serial 
differentiation 
by Coculture
Defined chemical 
conditions
Coating (Fibronectin/  
CollagenIV/Matrigel)
Condition medium 
(Cytokines/GF;   
+/ - Serum)
Mechanical 
stimulation
Cell sorting for 
markers 
(CD34+/Flk1+/Sca1+)
Coating 
Condition medium 
(Cytokines/GF)
Cell sorting for 
markers
(CD31+/Flk1 +/CD144 +)
Vascular 
differentiation 
+ various cells  
from all 3 germ 
layers
+/ -
Feeder cell 
layers
• MEF
• stromal cells
• EC 
Cell sorting for 
markers 
(CD34+/Flk1+)
Dissociated 
undifferentiated 
ESC
Fig. 3. Schematic overview outlining differentiation approaches used for vascular differentiation from ESCs. Vascular cell differentiation is mainly induced by three culture
methodologies: initiation of differentiation through EBs, co-culture with ﬁbroblast feeder layers or mature target cells, and monolayer culture of ESCs in deﬁned chemical conditions
followed by culture manipulations. For increasing efﬁciency, these protocols require generally FACS or MACS for markers such as CD34, Flk1, Sca1 or CD144 to obtain the desired cell
type and a homogenous cell population.
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ymatrices such as collagen IV (Pepe et al., 2010), ﬁbronectin (Blancas
et al., 2011; Kane et al., 2010) or Matrigel (Park et al., 2010), the use of
combination of differentiation stimuli including the addition of GFs/
Cytokines (Park et al., 2010; Vo et al., 2010), retinoic acid (Huang et al.,
2006; Xie et al., 2009), hypoxia (Prado-Lopez et al., 2010), or mechan-
ical force stimulation (Masumura et al., 2009; Shimizu et al., 2008),
were all shown to be able to potentially increase the yield, quality and
differentiated state of ESC-derived vascular cells. However, obtaining a
pure vascular cell population as ﬁnal product still requires to isolate
progenitor cells expressing markers such as CD34, Flk1 or Stem Cell
Antigen (Sca)-1 during ESC differentiation (Park et al., 2010; Xiao et al.,
2007; Yamashita et al., 2000).
Studies focused also on the adaptation of newdifferentiationprotocols
to clinical use requirements, including the removal of animal product
contamination from animal derived feeder and serum replacement to
avoid xeno-contamination. In particular, Lagarkova et al. have developed
an efﬁcient serum-free culture medium with a cocktail of GFs to differ-
entiate hESCs into endothelial primary culture (CD31+ and VE-
Cadherin+ cells), with about 50% of efﬁciency after 4 days (Lagarkova et
al., 2008). Anothermethod employed cell spheroids generated byﬂoating
culture of hESCs cultivated in feeder-free conditions with different
cytokines to generate, without requiring any pre-sorting processes, vas-
cular ECs (Nakahara et al., 2009). Recently, we reported a feeder- and
serum-free system for directed endothelial differentiation of a trans-
plantable hESC-derived EC population (Kane et al., 2010). In this study,
which was performed on the Cellartis ESC lines SA461 and SA121,
differentiating hESC-ECs revealed rapid loss of pluripotency markers and
progressive gain of vascular endothelial antigenic identity concomitant
with endothelial differentiation, to yield 81.59±2.11% CD31+/VE-
Cadherin+ cells at day 21. These cells display classical EC morphology
and behave as typical ECs in vitro and in vivo. More recently, fully deﬁned
and serum-freemedium containing the BMP4was shown to enhance the
differentiation of mESCs and hESCs toward the hematopoietic and
endothelial lineages (Chiang and Wong, 2011; Chicha et al., 2011).
Moreover, Blancas et al. have also explored the development of two new
different medium formulations for deriving ECs from mESCs using only
chemically deﬁned reagents. They also showed that the ﬁbronectin, and
not collagen type-IV, is the optimal substrate for EC induction in their
chemically deﬁned medium formulation (Blancas et al., 2011).The aforementioned achievements suggest the feasibility of pro-
duction of vascular cells from differentiating ESCs. However, prior to
clinical use of ESC-derived cells, signiﬁcant scientiﬁc obstacles must be
resolved with the current differentiation protocols. Therefore, the
crucial mechanisms and signaling pathways inﬂuencing ESC differ-
entiation towards the vascular lineage need to be better deﬁned. This
should facilitate the development of more efﬁcient strategies im-
proving robust production, isolation and scalability of desired vas-
cular cells and ensuring sufﬁcient cell numbers for transplantation.
Among the different signaling pathways involved in ESC vascular
differentiation (VEGFs, PDGFs, TGF-β, ROS, HDACs, Wnt, Notch, etc.),
microRNAs (miRs) have recently emerged as critical modulators of
both the maintenance of pluripotency and vascular differentiation of
stem cell by regulating gene expression (Howard et al., 2011; Kane et
al., 2012).
miRs are a class of endogenous small non-coding RNA, which post-
transcriptionally negatively regulate the expression of their target
genes. miRs are expressed in a variety of cell types, including ESCs
(Howard et al., 2011; Kim et al., 2009) and vascular cells (Caporali and
Emanueli, 2011). ThemiR-290 cluster constitutes over 70% of the entire
miRNA population in pluripotent mESCs and is downregulated upon
ESC differentiation. It enhances the unique stem cell cycle. A subset of
this cluster (miR-291-3p, miR-294, and miR-295) has been used to
promote cell reprogramming to pluripotency (Judson et al., 2009).
Similarly, the miR-302–367 cluster, which is transcriptionally induced
byOct3/4, Sox2 andNanog (Barroso-del Jesus et al., 2009), regulates cell
cycle in hESCs promoting self-renewal and pluripotency. miRs of this
cluster can help reprogramming of human ﬁbroblasts to induced pluri-
potent stem cells (Subramanyam et al., 2011).
miRs are necessary for vascular cell growth, differentiation, and
function (Albinsson et al., 2010; Caporali and Emanueli, 2011; Howard
et al., 2011). miR-126 is highly expressed in ECs and is involved in
endothelial function, whereas miR-145 is expressed in pericytes and
vascular smooth muscle cells (Cordes et al., 2009; Larsson et al., 2009).
miRs control vascular growth with their pro-angiogenic or anti-
angiogenic activities (Caporali and Emanueli, 2011). Importantly,
hypoxia modulates miR expression. For example, hypoxia upregulates
the expression of the pro-angiogenicmiR-210, which in turnmodulates
EC response to hypoxia (Fasanaro et al., 2008).
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regulating the expression levels of differentmiRs such asmiR-99b,miR-
181a/b,miR-10a andmiR-143/145 (Howard et al., 2011;H. Huang et al.,
2010; Kane et al., 2012; Kazenwadel et al., 2010). miR-1 can promote
smoothmuscle cell differentiation by repressingKLF-4 (Xie et al., 2011).
Consequently, the simple manipulation of miRs could be a prominent
strategy for ESC vascular derivation, increasing efﬁcacy and safety of SC
therapy.
4.2. Embryonic stem cell-derived vascular cell characterization
A combination of classic hallmarks based on vascular cell morphol-
ogy, functional assays and expression of speciﬁc markers is required to
identify and characterize ESC-derived vascular cells (Fig. 1).
ESC-derived ECs acquire cobblestone morphology in vitro. They
uptake acetylated low-density lipoprotein (Ac-Dil-LDL) and can gener-
ate tube-like structure formation in Matrigel (Park et al., 2010). For in
vivo assay, ESC-ECs can form a tube-like structurewithin aMatrigel plug
(Li et al., 2009a). A full range of EC lineage-speciﬁc markers such as
CD31/PECAM-1, CD34, Flt1/VEGFR-1, Flk1/VEGFR-2, CD144/VE-Cad-
herin, CD106/Vascular Cell Adhesion Protein (VCAM)-1, endothelial
nitric oxide synthase (eNOS), Tyrosine kinase with immunoglobulin-
like and EGF-like domains (Tie)1 and Tie2, and von Willebrand Factor
(vWF) are expressed in a time-dependent manner in ESC-ECs (Vittet et
al., 1996). Flk1 is one of the earliest markers appearing during the
endothelial lineage development, at around days 3–4 of differentiation
(Li et al., 2007). On the other hand, expression of VE-Cadherin and vWF
is known as late or mature EC markers. However, as mentioned above,
some markers (PECAM, Flk1, vWF, and Ac-Dil-LDL uptake) commonly
used for identiﬁcation of ESC-derived ECs are also shared by hemato-
poietic stem cells and hematopoietic progenitor cells (Kim and von
Recum, 2008). Moreover, Flk1 is robustly expressed in undifferentiated
hESCs (T. Chen et al., 2007; Li et al., 2008) and angioblasts (Nishikawa et
al., 2008) and thus these markers are not sufﬁcient for exclusive
endothelial selection from differentiating ESC. Hence, more mature EC
markers such as VE-Cadherin and Tie1 may be better.
ESC–SMCs exhibit typical spindle shape morphology which distin-
guishes them from other cell types. ESC–SMCs are deﬁned by their
abundant expression of SMC-speciﬁc isoforms of contractile protein,
such as alpha smooth muscle actin (αSMA), smooth muscle myosin
heavy chain (SMMHC), smoothelin, calponin, smooth muscle protein
22α (SM22α), calmodulin and h-caldesmon (Miano, 2010). Many
different elements of the contractile apparatus commonly conﬁrm
smooth muscle differentiation, but no marker is deﬁnitive for VSMCs.
αSMA is well expressed in differentiated VSMCs, even if it is also
expressed in a variety of non-VSMC types including skeletal and cardiac
muscle (Woodcock-Mitchell et al., 1988) and pericytes of some vascular
beds (Armulik et al., 2005). SM1 and SM2, isoforms of SMMHC, indicate
the degree of maturation of ESC–SMCs (Sinha et al., 2004) and were
shown to be VSMC-speciﬁc in mESC studies (Miano et al., 1994).
Smoothelin is also a marker of mature contractile VSMCs. However,
characterizing functional ESC–SMCs based just on SMC markers is not
sufﬁcient. Contractility is an important functional hallmark of mature
SMCs; they can contract in culture in response to pharmacological
agonists such as Carbachol or KCl (Xiao et al., 2009). Moreover, under
serum-containing culture conditions, ESC–SMCs are characterized by
their proliferative capacity (Cheung and Sinha, 2011) as they tend to
switch from a non-dividing contractile phenotype to a proliferative
synthetic phenotype (Owens et al., 2004). During this switch,
expression of most of these SMC markers is downregulated.
Pericytes differ from VSMCs in their relationship with ECs; as they
have direct physical contact with ECs. Pericytes express a number of
markers of differentiation such as αSMA, desmin, chondroitin sulfate
proteoglycan marker NG-2, PDGFR-β, CD146, aminopeptidases A and
N and the regulator of G-protein signaling (RGS5) (Armulik et al.,
2005; Tarnok et al., 2010). However, pericytes and VSMCs sharedsome structural and functional properties such as contractile ability
and the expression of αSMA. Thus despite a variety of markers,
pericytes have poor speciﬁcity and no single marker is able to identify
all pericytes (Hall, 2006), making their characterization more difﬁcult
(Cheung and Sinha, 2011).
4.3. In vitro model mimicking vascular development: embryoid bodies in
2D and 3D models
As mentioned above, EBs represent a “physiological” in vitro model
for the in vivo formation of the three germ layers (ectoderm,mesoderm
and endoderm) and their subsequent differentiation into mature cell
phenotypes. EBs are obtained through aggregation of ESCs in hanging
drops. The removal of feeder cells and LIF during 4 days allows their
growth and differentiation from ESCs. Hemangioblast, the precursor
common for ECs and hematopoietic cells, can be detected in the EB at
day 3, demonstrating the onset of vasculogenesis. EBs are then seeded
into a two-dimensional (2D) or embedded into a 3D collagen gel where
angiogenesis occurs, generating a primary vascular plexus at day 6. This
process is regulated by GFs. Indeed, addition of VEGF-A165, FGF-2 or
PDGF-BB stimulates the vascular plexus expansion, with differences in
2D and 3Dmodels. In general, addition of VEGF-A165 induces formation
of a peripheral vascular plexus in the 2Dmodel and the sprouting of ECs
in the 3D model (Jakobsson et al., 2007). In the 3D model, pericytes
surround EC sprouts and a lumen formation is detectable at about day
10 (Jakobsson et al., 2007). During this process, endothelial markers
such as CD31, Flk1, vWF, VE-Cadherin and Tie1, and smooth muscle
markers including αSMA and Vimentin, are detected in a time-
dependent manner in EBs (Martinez-Estrada et al., 2010; Vittet et al.,
1996).
Vascular formation studies with EB models offer several important
advantages including the possibility to isolate vascular lineage-speciﬁc
cells at different development stages for molecular, biochemical or
functional studies using induction and selection strategies. This model
allows access at the earliest stages of vascular development and in-
vestigates the inducing and patterning properties of soluble factors.
Genetic manipulations with gene loss or gain of function can be also
generated in ESCs. Inactivation of gene with a vascular function (Flk1,
VEGF-A165, VE-Cadherin, PDGFR-β) leads to similar phenotypes in the
EB model as observed in vivo (Jakobsson et al., 2006, 2007). Moreover,
the tracking of the spatial and temporal expression of a gene of interest
is possible by the generation of reporter cell lines (Fraser et al., 2005).
Thus the EBmodel offers a multifunctional platform for the discovery of
genes of unknown function in vascular formation and serves as an
elegant model for developmental biology and cell therapy of CVD.
5. Potential uses of embryonic stem cells in vascular regenerative
medicine
Therapeutic neovascularization is a promising option for treating
peripheral artery diseases, ischemic heart diseases, and cerebral ischemia.
The large proliferative capacity of hESCs and their pluripotentiality offer a
solution to treat CVD as they can differentiate into vascular cells. Animal
experiments have demonstrated promising results of hESC-vascular cell
transplantation (Table 1), showing that ESC-derived ECs and mural cells
incorporate into the vasculature of the infarcted myocardium, thus
improving cardiac remodeling and function (Christoforou et al., 2010;
Oyamada et al., 2008; Singla et al., 2006). Tracking the fate of hESC-
derived ECs, survival of transplanted cells into infarcted murine myo-
cardium was detected at 8 weeks post-infarct, and associated with
functional improvement and increased vascular density (Li et al., 2007,
2009b). In an immunocompromised mouse model of limb ischemia,
transplantation of hESC-ECs alone or with hESC–SMCs could improve
blood perfusion and limb salvage by facilitating postnatal neovasculariza-
tion, but adult ECs could not (Cho et al., 2007; N.F. Huang et al., 2010;
Kane et al., 2010; Lu et al., 2007; Sone et al., 2007; Yamahara et al., 2008).
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yWang et al. demonstrated that, after transplantation of hESC-derived ECs
into severe combined immunodeﬁcient (SCID) mice, the differentiated
cells contributed to arborized blood vessels that integrated into the host
circulatory systemand served as blood conduits for 150 days (Wang et al.,
2007).
The stability of mature ESC-vascular cells injected in host tissue is a
pre-requisite to improve efﬁciency in stem cell therapy. However,
highly differentiated cells may lose their therapeutic potential (Sone et
al., 2007; Yang et al., 2004). A better understanding of the different
development stages could improve obtainingmature cells which retain
therapeutic potential. For example, as mentioned above, several data
support the concept of an endothelial origin of HSCs (Lancrin et al.,
2009; Zovein et al., 2008). Few laboratories have addressed the gen-
eration of hemogenic endothelium from ESCs. Chiang and Wong have
started to summarize the different steps and factors necessary for the
transition between ESCs into endothelial and hematopoietic precursors.
They evidenced the essential role of BMP4 to generate hemogenic
endothelium from ESCs (Chiang and Wong, 2011). The generation of
ESC-ECs which could retain their hemogenic potential, could open new
therapeutic perspectives. However, this would need additional in vivo
research.
The successful animal experiments point to potential applications
for hESC-based therapies for various ischemic diseases. However, there
are signiﬁcant obstacles that need to be overcome before clinical
applications. These include animal product contamination, tumorige-
nicity and immunocompatibility. hESC lines generated in the presence
of animal serum and animal-derived feeder cells should not be used for
human therapeutic applications due to the risk of graft rejection and
pathogenic transmission from animal sources. Several different types of
human feeders such as human adult skin ﬁbroblasts (Richards et al.,
2002), or poly-D-lysine coating (Harb et al., 2008) could be an al-
ternative to prolong the growth of undifferentiated hESCs. Another
major risk involving the use of hESCs is the possibility that they form
teratomas following transplantation (Li et al., 2008). It is important to
use only differentiated cells to minimize the probability of teratomas.
Moreover, effective prevention of graft rejection is also needed after cell
transplantation because ESC-derived vascular cells will express trans-
plant antigens including human leukocyte antigens (HLAs). The crea-
tion of a bank of HLA-typed human ESC helping to reduce the likelihood
of graft rejection has been proposed (Nakajima et al., 2007). Finally, the
clinical use of hESC for SC therapy remains object of ethical debate.
The discovery of Yamanaka and colleagues that ectopic expression of
deﬁned transcription factors could reprogram somatic cells to pluripo-
tency offered a ground-breaking advancement in regenerative medicine
(Takahashi and Yamanaka, 2006). Induced pluripotent stem cells (iPSCs)
have been shown to differentiate into ECs (Rufaihah et al., 2011) and
mural cells (Narazaki et al., 2008; Xie et al., 2009). The delivery of hiPSCs-
derived ECs in a mouse limb ischemia model was shown to increase
capillary density and improve reperfusion (Rufaihah et al., 2011). iPSCs
could be an alternative to circumvent some therapeutic limitations
encounteredwith ESCs. For example, iPSCs-derived cells could be used for
autologous transplantation. However, as for ESCs, the immunogenicity of
iPSCs still needs to be evaluated before any clinic application, as
differentiated iPSCs have recently been shown to express an abnormal
gene inducing T-cell-dependent immune response after syngeneic
grafting (Zhao et al., 2011). Moreover, the need for genetic manipulation
and the variability of reprogramming iPSCs affecting their efﬁciency,
reproducibility and quality represent caveats, with a potential of
oncogenicity for recipients (Gonzalez et al., 2011).
Although promising results have been achieved, hESC-based vas-
cular cell therapy remains complex due to the difﬁculty of obtaining cell
integration into the host tissue. Further improvements in cell delivery
and engraftment are needed to enhance survival and functionality of
ESC-derived vascular cells after their transplantation (Li et al., 2009b).
However, we reported long-term vascular engraftment of hESC-derived
ECs in blood perfused murine vessels (Kane et al., 2010). This suggeststhe possibility that different ESC lines and/or differentiation protocols
may result in variable engraftment capacity of transplanted cells.
Various biomaterials have been explored to direct hESC differentiation
into microvasculatures networks by providing both biochemical and
biophysical cues. They can be classiﬁed as natural (hydrogels) or syn-
thetic (biodegradable polymer scaffold) biomaterials (Hanjaya-Putra
and Gerecht, 2009). There are two approaches for hESC use in tissue
engineering constructs (Korin and Levenberg, 2007). The ﬁrst is to in
vitro differentiate SCs into the desired cell types and then assemble the
cells into scaffolds. In fact, hESC-derived endothelial progenitor cells,
seeded onto highly porous biodegradable polymer scaffolds, formed
blood vessels that appeared to merge with the host vasculature when
implanted into immunodeﬁcient mice (Levenberg et al., 2002). The
other approach is to seed undifferentiated ESCs directly onto scaffolds
and then differentiate them in situ. Immortalized EC-derived from
mESCs was used to endothelialize hybrid grafts made of a SMC layer on
a polyglycolic acid scaffold. After subcutaneous implantation into nude
mice, the grafts presented a typical blood vessel structurewith EC lining
and a vessel wall composed of SMC and collagen. However, the graft
was not tested for mechanical strength or in vivo ﬂow patency (Shen et
al., 2003). In another study, mESCs were added to a compliant mic-
roporous tube made of polyurethane and differentiated into ECs and
SMCs with wall shear stress and circumferential strain loading in vitro
(Huang et al., 2005). Moreover, Nourse et al. have generated a
functional endothelium from hESCs seeded on porous scaffold trans-
planted into dorsal subcutaneous pockets (Nourse et al., 2010). More
recently, the transplantation of hESCs embedded in synthetic hydrogel
generated a functional microvascular graft which could preserve
cardiac structure and function when delivered to the infracted heart
(Kraehenbuehl et al., 2011).
The results of these aforementioned studies demonstrate the
complexity of hESC culture in 3D scaffolds. Despite all differenti-
ation studies done with hESCs, understanding and control hESCs
differentiation in 3D structures for tissue engineering require fur-
ther reﬁnements.
6. Conclusions
ESCs could be an unlimited source of vascular cells for treatment of
CVD. However, although the ﬁrst animal experiments are promising,
continued studies are needed to improve differentiation yield and
purity. Improvement in both in vitro cell culture systems and in vivo
translational studies to optimize the potential and function of hESC-
derived vascular cells could enable translation from experimental and
pre-clinical studies to human clinical therapies.
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